Neurol. praxi. 2024;25(5):368-372 | DOI: 10.36290/neu.2024.048

Treatment of Dravet syndrome

MUDr. Katalin Štěrbová, prof. MUDr. Pavel Kršek, Ph.D.
Klinika dětské neurologie 2. LF UK a FN v Motole, Praha

Dravet syndrome is a developmental and epileptic encephalopathy starting in infancy and its main features are drug -resistant epilepsy and several co-morbidities. Seizures are typically provoked by increased temperature. The treatment of Dravet syndrome is challenging. The first antiseizure drug should be valproic acid, while clobazam, stiripentol, fenfluramine, canabidiol or topiramate are usually added later. All the patients must have rescue medication for home management of seizures. Sodium channel blockers should not be used for chronic treatment, but phenytoin can be administered to stop status epilepticus. Non-pharmacological treatment of co-morbidities should be addressed as well.

Keywords: Dravet syndrome, stiripentol, fenfluramine, canabidiol.

Received: July 31, 2024; Revised: July 31, 2024; Accepted: August 5, 2024; Prepublished online: August 5, 2024; Published: November 19, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štěrbová K, Kršek P. Treatment of Dravet syndrome. Neurol. praxi. 2024;25(5):368-372. doi: 10.36290/neu.2024.048.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 19.11.2025

    References

    1. Bacq A, et al. An Update on Stiripentol Mechanisms of Action: A Narrative Review. Adv Ther. 2024 Apr;41(4):1351-1371. doi: 10.1007/s12325-024-02813-0. Go to original source... Go to PubMed...
    2. Battaglia D, Ricci D, Chieffo D, Guzzetta F. Outlining a core neuropsychological phenotype for Dravet syndrome. Epilepsy Res. 2016 Feb;120:91-7. doi: 10.1016/j.eplepsyres.2015. 11. 020. Go to original source...
    3. Berkovic SF, Harkin L, McMahon JM, et al. De­‑novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study. Lancet Neurol. 2006 Jun;5(6):488-92. doi: 10.1016/S1474-4422(06)70446-X. Go to original source... Go to PubMed...
    4. Brunklaus A, Brünger T, Feng T, et al. The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications. Brain. 2022 Nov 21;145(11):3816-3831. doi: 10.1093/brain/awac210. Go to original source... Go to PubMed...
    5. Claes L, et al. De novo mutations in the sodium­‑channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet. 2001 Jun;68(6):1327-32. doi: 10.1086/320609. Go to original source... Go to PubMed...
    6. Djémié T, Weckhuysen S, von Spiczak S, et al.; EuroEPINOMICS-RES Dravet working group. Pitfalls in genetic testing: the story of missed SCN1A mutations. Mol Genet Genomic Med. 2016 Apr 14;4(4):457-64. doi: 10.1002/mgg3.217. Go to original source... Go to PubMed...
    7. Dravet Ch, Guerrini R. Dravet syndrome. John Libbey Eurotext. 2023; 179 s. ISBN 978-2-7420-1653-2.
    8. Granata T. Comprehensive care of children with Dravet syndrome. Epilepsia. 2011 Apr;52 Suppl 2:90-4. doi: 10.1111/j.1528-1167.2011.03011.x. Go to original source... Go to PubMed...
    9. Howell KB, Butcher S, Schneider AL, et al. Complications of Influenza A or B Virus Infection in Individuals With SCN1A­‑Positive Dravet Syndrome. Neurology. 2023 Jan 24;100(4):e435-e442. doi: 10.1212/WNL.0000000000201438. Go to original source... Go to PubMed...
    10. Chemaly N, Kuchenbuch M, Teng T, et al. A European pilot study in Dravet Syndrome to delineate what really matters for the patients and families. Epilepsia Open. 2024 Feb;9(1):388-396. doi: 10.1002/epi4.12557. Go to original source... Go to PubMed...
    11. Chiron C, Helias M, Kaminska A, et al. Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood? Epilepsia. 2018 Sep;59(9):1705-1717. doi: 10.1111/epi.14536. Go to original source... Go to PubMed...
    12. Chiron C, Chemaly N, Chancharme L, Nabbout R. Initiating stiripentol before 2 years of age in patients with Dravet syndrome is safe and beneficial against status epilepticus. Dev Med Child Neurol. 2023 Dec;65(12):1607-1616. doi: 10.1111/dmcn.15638. Go to original source... Go to PubMed...
    13. Licheni SH, Mcmahon JM, Schneider AL, et al. Sleep problems in Dravet syndrome: a modifiable comorbidity. Dev Med Child Neurol. 2018 Feb;60(2):192-198. doi: 10.1111/dmcn.13601. Go to original source... Go to PubMed...
    14. Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 2002;16(10):669-94. doi: 10.2165/00023210-200216100-00003. Go to original source... Go to PubMed...
    15. Reilly C, Bjurulf B, Hallböök T. Autism and attention­‑deficit/hyperactivity disorder in children with Dravet syndrome: A population­‑based study. Dev Med Child Neurol. 2024 Apr 26. doi: 10.1111/dmcn.15937. Go to original source... Go to PubMed...
    16. Strzelczyk A, Schubert­‑Bast S. A Practical Guide to the Treatment of Dravet Syndrome with Anti­‑Seizure Medication. CNS Drugs. 2022 Mar;36(3):217-237. doi: 10.1007/s40263-022-00898-1. Go to original source... Go to PubMed...
    17. Sullivan J, Benítez A, Roth J, et al. A systematic literature review on the global epidemiology of Dravet syndrome and Lennox­‑Gastaut syndrome: Prevalence, incidence, diagnosis, and mortality. Epilepsia. 2024 May;65(5):1240-1263. doi: 10.1111/epi.17866. Go to original source... Go to PubMed...
    18. Scheffer IE. The fascinating phenotypic spectrum of SCN1A gain­‑of­‑function epilepsies. Epilepsia. 2023 May;64(5):1348-1350. doi: 10.1111/epi.17562. Go to original source... Go to PubMed...
    19. Suzuki T, Natsume J, Ito Y, et al. Effect of levodopa on pathological gait in Dravet syndrome: A randomized crossover trial using three­‑dimensional gait analysis. Epilepsia. 2024 May;65(5):1304-1313. doi: 10.1111/epi.17888. Go to original source... Go to PubMed...
    20. Symonds et al., Incidence and phenotypes of childhood­‑onset genetic epilepsies: a prospective population­‑based national cohort. Brain. 2019: 142; 2303 -2318. doi:10.1093/brain/awz1952318. Go to original source...
    21. Thanh TN, Chiron C, Dellatolas G, et al. Efficacité et tolérance à long terme du stiripentol dans le traitement de l'épilepsie myoclonique sévère du nourrisson (syndrome de Dravet) [Long­‑term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet's syndrome)]. Arch Pediatr. 2002 Nov;9(11):1120-7. French. doi: 10.1016/s0929-693x(02)00090-8. PMID: 12503502. Go to original source... Go to PubMed...
    22. Wirrell EC, Hood V, Knupp KG, et al. International consensus on diagnosis and management of Dravet syndrome. Epilepsia. 2022 Jul;63(7):1761-1777. doi: 10.1111/epi.17274. Go to original source... Go to PubMed...
    23. Zuberi SM, Wirrell E, Yozawitz E, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022 Jun;63(6):1349-1397. doi: 10.1111/epi.17239. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.